Moderna receives u.s. fda approval for rsv vaccine mresvia(r)

Mresvia is moderna's second approved product and the only rsv vaccine available in single-dose pre-filled syringes cambridge, ma / accesswire / may 31, 2024 / moderna, inc. (nasdaq:mrna) today announced that the u.s. food and drug administration (fda) has approved mresvia (mrna-1345), an mrna respiratory syncytial virus (rsv) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by rsv infection. the approval was granted under a breakthrough therapy designation and marks the second approved mrna product from moderna.
MRNA Ratings Summary
MRNA Quant Ranking